Causal roles of phenotypic age and metabolic health on dementia: a Mendelian randomisation and structure learning study
Baousi, A.; Dobinda, K.; Zhu, J.; Yu, X.; Muir, K.; Lophatananon, A.; McMillan, B.; Clarkson et al.. medRxiv (preprint), 2026-09-03
Topic: Risk, prevention and care in population studies
Plain-language summary
BackgroundPhenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes. Independent genome-wide significant variants were used as genetic instruments in two-sample Mendelian randomisation (MR) with FinnGen all-cause dementia summary statistics. FindingsGWAS identified 126 and 141 independent genome-wide significant variants for MetaboHealth and PhenoAgeAccel, of which 109 and 141 were retained as genetic instruments. Longitudinal studies linked PhenoAgeAccel, derived from PhenoAge, to incident all-cause, young-onset, and late-onset dementia, dementia subtypes, cognition, and brain structure; MetaboHealth was associated with poorer cognitive performance, 10-year cognitive decline, and reduced functional independence.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 272 participants. This study used genetic methods to examine whether biological aging and metabolic health have causal roles in dementia, and linked these measures to dementia outcomes and cognition in longitudinal data. It identifies possible risk factors and does not test any treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Baousi, A., Dobinda, K., Zhu, J., Yu, X., Muir, K., Lophatananon, A., et al. (2026). Causal roles of phenotypic age and metabolic health on dementia: a Mendelian randomisation and structure learning study. medRxiv (preprint). https://doi.org/10.64898/2026.09.01.26360731
Vancouver
Baousi A, Dobinda K, Zhu J, Yu X, Muir K, Lophatananon A, et al. Causal roles of phenotypic age and metabolic health on dementia: a Mendelian randomisation and structure learning study. medRxiv (preprint). 2026. doi:10.64898/2026.09.01.26360731.
BibTeX
@article{baousi2026-eb840701,
author = {Baousi, A. and Dobinda, K. and Zhu, J. and Yu, X. and Muir, K. and Lophatananon, A. and McMillan, B. and Clarkson and others},
title = {{Causal roles of phenotypic age and metabolic health on dementia: a Mendelian randomisation and structure learning study}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.09.01.26360731},
url = {https://doi.org/10.64898/2026.09.01.26360731}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- BackgroundPhenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes.
- Independent genome-wide significant variants were used as genetic instruments in two-sample Mendelian randomisation (MR) with FinnGen all-cause dementia summary statistics.
- FindingsGWAS identified 126 and 141 independent genome-wide significant variants for MetaboHealth and PhenoAgeAccel, of which 109 and 141 were retained as genetic instruments.
- Longitudinal studies linked PhenoAgeAccel, derived from PhenoAge, to incident all-cause, young-onset, and late-onset dementia, dementia subtypes, cognition, and brain structure; MetaboHealth was associated with poorer cognitive performance, 10-year cognitive decline, and reduced functional independence.
Why it matters
This study used genetic methods to examine whether biological aging and metabolic health have causal roles in dementia, and linked these measures to dementia outcomes and cognition in longitudinal data. It identifies possible risk factors and does not test any treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designlongitudinal study
- Participants272
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 36 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 34 of the 94 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 272 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Hui Yan Guo: h-index 28 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 34 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 94 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.